Terms: = Skin cancer AND IDH1, IDP, 3417, ENSG00000138413, IDH, PICD, O75874 AND Prognosis
4 results:
1. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
2. PLEKHA4 Is a Prognostic Biomarker and Correlated with Immune Infiltrates in Glioma.
Zhang W; Li L; Bian PP; Luo QP; Xiong ZT
Biomed Res Int; 2023; 2023():4504474. PubMed ID: 36714030
[TBL] [Abstract] [Full Text] [Related]
3. Hsa-miR-27a-3p and epidermal growth factor receptor expression analysis in glioblastoma FFPE samples.
Salmani T; Ghaderian SMH; Hajiesmaeili M; Rezaeimirghaed O; Hoseini MS; Rakhshan A; Nasiri MJ; Ghaedi H; Akbarzadeh R
Asia Pac J Clin Oncol; 2021 Oct; 17(5):e185-e190. PubMed ID: 33029912
[TBL] [Abstract] [Full Text] [Related]
4. Cutaneous Melanocytic Tumors With Concomitant NRASQ61R and idh1R132C Mutations: A Report of 6 Cases.
Macagno N; Pissaloux D; Etchevers H; Haddad V; Vergier B; Sierra-Fortuny S; Tirode F; de la Fouchardière A
Am J Surg Pathol; 2020 Oct; 44(10):1398-1405. PubMed ID: 32732488
[TBL] [Abstract] [Full Text] [Related]
